{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:42:04Z","timestamp":1790080924843,"version":"4.0.1"},"reference-count":68,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. The present publication represents a consensus document from a series of meetings held during 2017. The Panel generated clinical key questions using the criterion of clinical relevance through a Delphi process and explored 4 domains, ie, diarrhea\/colitis, transaminitis, pneumonitis, and infectious complications. Using the consensus method, the Panel was able to shape recommendations which may assist hematologist to minimize adverse events and guarantee adherence to treatment in patients with CLL and FL candidate to receive idelalisib.<\/jats:p>","DOI":"10.1002\/hon.2540","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T04:59:10Z","timestamp":1536209950000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-1308","authenticated-orcid":false,"given":"Antonio","family":"Cuneo","sequence":"first","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero\u2010Universitaria, Arcispedale S. Anna University of Ferrara  Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"IRCCS Policlinico S. Matteo Foundation  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[{"name":"Gastroenterology and Transplant Hepatology \u201cPapa Giovanni XXIII\u201d Hospital  Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita\u2010Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Marzano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, San Giovanni Battista Hospital University of Torino  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Montillo","sequence":"additional","affiliation":[{"name":"Department of Hematology Niguarda Cancer Center Niguarda Hospital Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venerino","family":"Poletti","sequence":"additional","affiliation":[{"name":"Department of Diseases of the Thorax Ospedale GB Morgagni  Forl\u00ec Italy"},{"name":"Department of Respiratory Diseases &amp; Allergy Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Teaching Hospital S. Orsola\u2010Malpighi Alma Mater Studiorum \u2010 University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology Lorenzo e Ariosto Ser\u00e0gnoli University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.88.3801172"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271171"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.008"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-757740"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630947"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"issue":"15","key":"e_1_2_6_16_1","article-title":"Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment","volume":"34","author":"Brown JR","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.1994.tb01066.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0304-0"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.495"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2898-1"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.504"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3801"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000522"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164103"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000525"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4391.4391"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.009"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29344"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29364"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1384815"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080106"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786566"},{"issue":"1","key":"e_1_2_6_34_1","article-title":"Risk factors for grade 3\/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib","volume":"130","author":"Brown JR","year":"2017","journal-title":"Blood"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633156"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3091.3091"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01670-2015"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-216343"},{"key":"e_1_2_6_41_1","unstructured":"Center for drug evaluation and research.Application number 205858Orig1s000; medical review (s): pag 65. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205858Orig1s000MedR.pdf. Accessed May 16 2018."},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177"},{"key":"e_1_2_6_43_1","first-page":"951","article-title":"Pneumopathies intrestitielles iatrogeniques","volume":"64","author":"Bonniaud P","year":"2014","journal-title":"Rev Prat"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000076670"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0320ST"},{"issue":"2","key":"e_1_2_6_46_1","first-page":"65","article-title":"Diagnostic role of rapid on\u2010site cytologic examination (ROSE) of broncho\u2010alveolar lavage in ALI\/ARDS","volume":"104","author":"Ravaglia C","year":"2012","journal-title":"Pathologica"},{"key":"e_1_2_6_47_1","first-page":"36","article-title":"The role of transbronchial lung biopsy for the diagnosis of diffuse drug\u2010induced lung disease: a case series of 44 patients","volume":"25","author":"Romagnoli M","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.08.002"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1820-0"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.6338"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-702761"},{"key":"e_1_2_6_52_1","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell IB","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.12.033"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw157"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.18869\/acadpub.cmm.1.1.42"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00157-2017"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.049"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12599"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw155"},{"key":"e_1_2_6_61_1","unstructured":"Geneva: World Health Organization.Guidelines on the management of latent tuberculosis infection.2015."},{"issue":"4","key":"e_1_2_6_62_1","first-page":"iv149","article-title":"Appendix 4: chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org\/Guidelines\/Haematological\u2010Malignancies)","volume":"28","author":"ESMO Guidelines Committee","year":"2017","journal-title":"Ann Oncol"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3592"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15080"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2503"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21406"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T14:38:17Z","timestamp":1694356697000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/hon.2540"],"URL":"https:\/\/doi.org\/10.1002\/hon.2540","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"2018-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}